Really don’t understand the reason behind such deep corrections in the diagnostic stocks today. The results are positive, in fact exactly what one should expect from the company. Covid revenue now accounts for only 2% of the total revenues this quarter and margins also look stable. Even with covid revenue going down, non-covid revenue has been considerably higher than the pre-covid levels and also shows 9% growth this quarter. With increasing reach to new markets by the way of introducing newer labs and given the poor healthcare conditions in our country, growth of diagnostic sector is very important. But still don’t understand the reason behind the fall.
| Subscribe To Our Free Newsletter |
